China I&R, Qeeka Home to pre-market Hong Kong IPOs

China Isotope & Radiation and Qeeka Home are both set to start pre-marketing tomorrow for Hong Kong IPOs of about US$200m each, according to people close to the deals.

China I&R makes diagnostic and therapeutic radiopharmaceutical products for medical and industrial applications. CICC is the sole sponsor.

China National Nuclear Corp controls 53.98% of the company through direct and indirect holdings, including a direct stake of 44.47%.

According to a regulatory filing, the company posted a net profit of Rmb476m (US$74m) in 2017, up 9.5% year on year.

Qeeka Home, which operates an online interior design and construction platform in China, plans to pre-market the float for around a week, say two of the people.

The company posted a loss of Rmb856m (US$136m) for 2017, versus a loss of Rmb410m for 2016. CLSA and Goldman Sachs are joint sponsors.